Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03835533
Title Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Parker Institute for Cancer Immunotherapy

prostate cancer


CDX-301 + INO-5151 + Nivolumab

CDX-301 + Nivolumab + Poly ICLC

Nivolumab + NKTR-214

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Angeles Clinic Los Angeles California 90025 United States Details
University of California San Francisco San Francisco California 94158 United States Details
Mount Sinai New York New York 10029 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Oregon Health & Science University Portland Oregon 97239 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field